MET and non-small cell lung carcinoma: According to previous clinical trials, NSCLC patients harboring METex14del responded well to MET‐tyrosine kinase inhibitors (TKIs), including crizotinib, tepotinib, capmatinib, and cabozantinib.6, 7, 8, 9